Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...
Solid Investment Potential: Buy Rating for Gilead Sciences Amid Positive Revenue Adjustments and Growth Commitment
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...
Fintel on MSN3d
Bernstein Initiates Coverage of Gilead Sciences (GILD) with Outperform Recommendation
Fintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...
Benzinga.com17d
Peeling Back The Layers: Exploring Gilead Sciences Through Analyst Insights
Gilead Sciences GILD underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their ...
The Indian Express17d
Biopharma firm Gilead announces lenacapavir licensing for HIV treatment
International AIDS Society, an association of HIV/AIDS professionals, applauded moves by Gilead Sciences, a biopharma company, to make the generic injectable lenacapavir for HIV prevention widely ...
Reuters17d
Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda
Oct 3 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Thursday it would donate about 5,000 vials of its antiviral drug remdesivir to the Rwanda Medical Supply for emergency use in ...
AllAfrica.com17d
Rwanda: Marburg Virus - Gilead Confirms Remdesivir Drug Donation to Rwanda
American biopharmaceutical company Gilead Sciences, on Thursday, October 3, announced that it will donate about 5,000 vials of its antiviral drug Remdesivir for emergency use in response to the ...
Africa Science News18d
IAS calls for global access as Gilead announces lenacapavir licensing
IAS – the International AIDS Society has lauded moves by Gilead Sciences to make generic injectable lenacapavir for HIV prevention widely available, but cautions that the current agreements still ...
Business Line18d
Gilead inks pact with six generic drugmakers on long-acting HIV injectable, even as civil society oppose patent application
Six drugmakers have inked voluntary licensing (VL) agreements with Gilead Sciences to manufacture ... Act does not grant monopolies on established science, such as the salt forms of lenacapavir ...
Pharmabiz18d
UNAIDS welcomes Gilead’s voluntary licensing agreements on HIV drug lenacapavir
The Joint United Nations Programme on HIV/AIDS (UNAIDS) welcomed US-based Gilead Science's announcement of voluntary licensing of its long acting HIV drug lenacapavir for generic production, and asked ...
Armed robbery in Revesby18d
UNAIDS Reacts to Gilead's Lenacapavir Licensing Deal
Responding to today's announcement by Gilead on lenacapavir, UNAIDS Executive Director Winnie Byanyima said: "We welcome Gilead's announcement of licensing the break-through HIV medicine lenacapavir ...
Reuters18d
Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries
Oct 2 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell cheaper copycat versions of its ...